Market Research Logo

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025

Summary

Hepatitis C virus (HCV) is a small, enveloped RNA virus that causes acute and chronic infections of the liver and, if left untreated, can result in fibrosis, permanent liver damage (cirrhosis), Hepatocellular carcinoma (HCC), and eventually death. A member of the Flaviviridae viral family and hepacivirus genus, HCV can be classified into six major genotypes, with many additional subtypes within each genotype. While genotype 1 (GT1) causes almost half of HCV infections, all six major genotypes (GT1-6) are prevalent worldwide.

The genetic diversity of HCV strains, even within the same host, originates from the low fidelity of the ribonucleic acid (RNA) polymerase, and is thought to account for viral resistance when HCV is treated with a single drug. During the last few years, the hepatitis C treatment landscape has experienced successive waves of revolutionary change, and is now dominated by high-performance regimens comprising a new generation direct acting antivirals (DAAs). Moreover, the hepatitis C market is set to experience a steady decline, falling from $21.7 billion in 2015 to $17.5 billion by 2025, representing a negative compound annual growth rate of 2.1%.

The report “PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025” states that this deterioration in sales, which will occur across the nine major markets (9MM) of the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, and China, will be due to recent advances made in hepatitis C treatment, which have resulted in high cure rates and reduced adverse effects for the vast majority of individuals with chronic hepatitis C infection.

The main market for direct-acting antivirals (DAAs) curing patients of hepatitis C in 2015 was the US, contributing to over 60% of the total market size. However, declining patient populations and unusually high DAA treatment rates in 2015 will reduce the disease prevalence in the US market to a more sustainable level, with the US contributing only 48% of sales in the 9MM by 2025.

Companies reviewed in this report: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen / Johnson & Johnson, Merck, Roche.

Scope

  • Overview of hepatitis C infections, including epidemiology, etiology, pathophysiology, regional genotype distribution, as well current routine treatment recommendations of all 9MM covered.
  • Topline hepatitis C market revenue from 2015-2025. Recent acquisitions, approvals and governmental recommendations and restrictions are included in the forecast model.
  • Key topics covered include dynamics in the number of prevalent cases during the forecast, market characterization, unmet needs, and company strategies.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.
  • Analysis of the current and future market competition in the global hepatitis C marketplace. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global hepatitis C market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the hepatitis C market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
3.3 Prognosis and Quality of Life
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global Trends
4.3.1 Diagnosed Incidence and Total Prevalence
4.3.2 Genotype
4.4 Forecast Methodology
4.4.1 Sources Used Tables
4.4.2 Forecast Assumptions and Methods
4.4.3 Sources Not Used
4.5 Epidemiological Forecast of HCV (2015-2025)
4.5.1 Total Prevalent Cases
4.5.2 Diagnosed Prevalent Cases
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 Limitations of the Analysis
4.6.3 Strengths of the Analysis
5 Disease Management
5.1 Diagnosis Overview
5.1.1 Initial Diagnosis and Referral
5.1.2 Patient Assessment
5.1.3 Viral Assessment
5.2 Treatment Guildines
5.3 US
5.3.1 Diagnosis
5.3.2 Treatment Guidelines
5.3.3 Clinical Practice and Coverage
5.4 5EU
5.4.1 Diagnosis Overview
5.4.2 Treatment Guidelines Overview
5.5 France
5.5.1 Diagnosis
5.5.2 Clinical Practice
5.6 Germany
5.6.1 Diagnosis
5.6.2 Clinical Practice
5.7 Italy
5.7.1 Diagnosis
5.7.2 Clinical Practice
5.8 Spain
5.8.1 Diagnosis
5.8.2 Clinical Practice
5.9 UK
5.9.1 Diagnosis
5.9.2 Clinical Practice
5.10 Japan
5.10.1 Diagnosis
5.10.2 Clinical Practice
5.11 Brazil
5.11.1 Diagnosis
5.11.2 Clinical Practice
5.12 China
5.12.1 Diagnosis
5.12.2 Clinical Practice
6 Competitive Assessment
6.1 Overview
6.2 Strategic Competitor Assessment
6.3 Major Brands - Fixed-Dose Combination Direct-Acting Antivirals
6.3.1 Harvoni (Ledipasvir/Sofosbuvir)
6.3.2 Viekira Pak (Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir) and Technivie (Ombitasvir/Paritaprevir/Ritonavir)
6.3.3 Zepatier (Elbasvir/Grazoprevir)
6.3.4 Epclusa (Sofosbuvir/Velpatasvir)
6.4 Major Brands - Single Component Direct-Acting Antivirals
6.4.1 Sovaldi (Sofosbuvir)
6.4.2 Daklinza (Daclatasvir)
6.4.3 Olysio (Simeprevir)
6.5 Major Brands - Peginterferon and Ribavirin
6.5.1 Pegasys (Peginterferon alfa-2a) and PegIntron (Peginterferon alfa-2b)
6.5.2 Copegus, Rebetol, and Generic Ribavirin
6.6 Other Branded Direct-Acting Antivirals
6.6.1 Incivek (Telaprevir) and Victrelis (Boceprevir)
6.6.2 Sunvepra (Asunaprevir)
6.6.3 Exviera (Dasabuvir)
6.6.4 Vanihep (Vaniprevir)
7 Unmet Needs and Opportunity Analysis
7.1 Overview
7.2 Reducing the Overall Cost Burden of Direct-Acting Antiviral Treatment Algorithms
7.2.1 Unmet Need
7.2.2 Gap Analysis
7.2.3 Opportunity
7.3 Increasing Awareness of Hepatitis C Treatment Opportunities
7.3.1 Adjusting the Approaches Physicians Take with Hepatitis C
7.3.2 Awareness in the General Population
7.4 Expanding Treatment Access
7.4.1 Unmet Need
7.4.2 Gap Analysis
7.4.3 Opportunity
7.5 Improving Diagnosis Rates in Patients with Chronic Hepatitis C Infection
7.5.1 Unmet Need
7.5.2 Gap Analysis
7.5.3 Opportunity
7.6 Reducing Frequency and Severity of Adverse Events in All Patient Groups
7.6.1 Unmet Need
7.6.2 Gap Analysis
7.6.3 Opportunity
7.7 Enhanced Cure Rates in Difficult-to-Treat Patients
7.7.1 Unmet Need
7.7.2 Gap Analysis
7.7.3 Opportunity
7.8 Clinical Evalulation of Direct-Acting Antiviral Efficacy in Pediatric Patients
7.8.1 Unmet Need
7.8.2 Gap Analysis
7.8.3 Opportunity
8 Pipeline Assessment
8.1 Overview
8.2 Clinical Trial Mapping
8.2.1 Clinical Trials by Status and Phase
8.3 Promising DAA Regimens in Clinical Development
8.3.1 Sofosbuvir/Velpatasvir/Voxilaprevir
8.3.2 Glecaprevir/pibrentasvir
8.3.3 Asunaprevir/Beclabuvir/Daclatasvir
8.3.4 MK-3682A and MK-3682B
8.3.5 Odalasvir-Based Regimens
8.4 Other Products in Clinical Development
8.4.1 Investigational Therapies with Established MOAs
8.4.2 Investigational Therapies with Novel MOAs
8.4.3 Clinical Development Outside 9MM
9 Current and Future Players
9.1 Overview
9.2 Trends in Corporate Strategy
9.3 Company Profiles
9.3.1 Gilead Sciences
9.3.2 AbbVie
9.3.3 Merck
9.3.4 Janssen
9.3.5 Bristol-Myers Squibb
9.3.6 Roche
9.4 Additional Companies with Promising Drugs
9.4.1 Regulus Therapeutics
9.4.2 Presidio Pharmaceuticals
9.4.3 Trek Therapeutics
10 Market Outlook
10.1 Global Markets
10.1.1 Forecast
10.1.2 Drivers and Barriers - Global Issues
10.2 US
10.2.1 Forecast
10.2.2 Key Events
10.2.3 Drivers and Barriers
10.3 5EU
10.3.1 5EU
10.3.2 France
10.3.3 Germany
10.3.4 Italy
10.3.5 Spain
10.3.6 UK
10.4 Japan
10.4.1 Forecast
10.4.2 Key Events
10.4.3 Drivers and Barriers
10.5 Brazil
10.5.1 Forecast
10.5.2 Key Events
10.5.3 Drivers and Barriers
10.6 China
10.6.1 Forecast
10.6.2 Key Events
10.6.3 Drivers and Barriers
11 Appendix
11.1 Bibliography
11.2 Abbreviations
11.3 Methodology
11.4 Forecasting Methodology
11.4.1 Patient Populations
11.4.2 Drugs Included in Each Therapeutic Class
11.4.3 Launch and Patent Expiry Dates
11.4.4 General Pricing Assumptions
11.4.5 Individual Drug Assumptions
11.4.6 Generic Erosion
11.4.7 Pricing of Pipeline Agents
11.5 Primary Research - KOLs and Payers Interviewed for this Report
11.5.1 KOLs
11.5.2 Payers
11.6 Primary Research - Prescriber Survey
11.7 About the Authors
11.7.1 Analysts
11.7.2 Therapy Area Director
11.7.3 Epidemiologists
11.7.4 Global Director of Therapy Analysis and Epidemiology
11.8 About GlobalData
11.9 Disclaimer
1.1 List of Tables
Table 1: Modes of HCV Transmission
Table 2: Symptoms of Acute and Chronic HCV Infection
Table 3: Risk Factors and Comorbidities Associated with HCV Infection
Table 4: 9MM, Anti-HCV+ Total Prevalence from 1988-2015
Table 5: Hepatitis C Virus Genotype Description
Table 6: 9MM, Sources Used to Forecast Anti-HCV+ Total Prevalent Cases
Table 7: 9MM, Sources Used to Forecast HCV RNA+ Total Prevalent Cases
Table 8: 9MM, Sources Used to Forecast Anti-HCV+ Total Prevalent Cases by HCV Genotypes
Table 9: 9MM, Sources Used to Forecast HCV/HIV Co-Infection Cases Among Anti-HCV+ Total Prevalent Cases
Table 10: 9MM, Sources Used to Forecast HCV/HBV Co-Infection Cases Among Anti-HCV+ Total Prevalent Cases
Table 11: 9MM, Sources Used to Forecast Anti-HCV+ Diagnosed Prevalent Cases
Table 12: 9MM, Sources Used to Forecast HCV RNA+ Diagnosed Prevalent Cases
Table 13: 9MM, Sources Used for Anti-HCV+ Diagnosed Prevalent Cases by Liver Cirrhosis Status
Table 14: 9MM, Sources Not Used in Epidemiological Forecast for Anti-HCV+ Total Prevalent Cases
Table 15: 9MM, Anti-HCV+ Total Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015-2025
Table 16. 9MM, Anti-HCV+ Total Prevalent Cases, by Age, Both Sexes, N (Row %), 2015
Table 17: 9MM, Anti-HCV+ Total Prevalent Cases, by Sex, All Ages, N (Row %), 2015
Table 18: 9MM, Anti-HCV+ Total Prevalent Cases, by HCV Genotype, All Ages, N (Row %), Both Sexes, 2015
Table 19: 9MM, HCV RNA+ Total Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015-2025
Table 20. 9MM, HCV RNA+ Total Prevalent Cases, by Age, Both Sexes, N (Row %), 2015
Table 21: 9MM, HCV RNA+ Total Prevalent Cases, by Sex, All Ages, N (Row %), 2015
Table 22: 9MM, Anti-HCV+ Diagnosed Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015-2025
Table 23: 9MM, Age-Specific Anti-HCV+ Diagnosed Prevalent Cases, Both Sexes, N (Row %), 2015
Table 24: 9MM, Anti-HCV+ Diagnosed Prevalent Cases, by Sex, All Ages, N (Row %), 2015
Table 25: 9MM, HCV RNA+ Diagnosed Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015-2025
Table 26: 9MM, Age-Specific HCV RNA+ Diagnosed Prevalent Cases, Both Sexes, N (Row %), 2015
Table 27: 9MM, HCV RNA+ Diagnosed Prevalent Cases, by Sex, All Ages, N (Row %), 2015
Table 28: HCV Genotypes Prevalent in the 9MM
Table 29: General Standard of Care by HCV Genotype in 2015
Table 30: Treatment Guidelines for Hepatitis C
Table 31: Country Profile - US
Table 32: Recommended Treatment Options for Treatment-Naïve Patients in the US, 2016
Table 33: Country Profile - 5EU
Table 34: Recommended Treatment Options for Treatment-naïve Patients in the 5EU, 2016
Table 35: Country Profile - Japan
Table 36: Country Profile - Brazil
Table 37: Country Profile - China
Table 38: Leading Treatments for Hepatitis C, 2016
Table 39: Harvoni - Clinical Trials Supporting Regulatory Approval
Table 40: Product Profile - Harvoni
Table 41: Key Clinical Trials of Gilead’s Harvoni
Table 42: Safety of Harvoni - Most Common AEs
Table 43: Harvoni SWOT Analysis, 2016
Table 44: Global Sales Forecasts ($m) for Harvoni, 2015-2025
Table 45: Viekira Pak and Technivie - Key Clinical Trials Supporting Regulatory Approval
Table 46: Product Profile - Viekira Pak and Technivie
Table 47: Efficacy of Viekira Pak and Technivie - SVR12, Key Phase III and Phase II Studies
Table 48: Safety of Viekira Pak and Technivie - Most Common AEs
Table 49: Viekira Pak and Technivie SWOT Analysis, 2016
Table 50: Global Sales Forecast ($m) for Viekira Pak, 2015-2025
Table 51: Zepatier - Key Clinical Trials Supporting Regulatory Approval
Table 52: Product Profile - Zepatier
Table 53: Efficacy of Zepatier - SVR12, Key Phase III and Phase II Clinical Trials
Table 54: Treatment-Emergent Amino Acid Substitutions Among Virologic Failures of Zepatier
Table 55: Safety of Zepatier - Most Common AEs
Table 56: Zepatier SWOT Analysis, 2016
Table 57: Global Sales Forecasts ($m) for Zepatier, 2015-2025
Table 58: Key Clinical Trials of Gilead’s Epclusa
Table 59: Product Profile - Epclusa
Table 60: Efficacy of Epclusa - SVR12, Key Phase III Trials
Table 61: Safety of Epclusa - Most Common AEs
Table 62: Epclusa SWOT Analysis, 2016
Table 63: Global Sales Forecasts ($m) for Epclusa, 2015-2025
Table 64: Sovaldi - Clinical Trials Supporting Regulatory Approval
Table 65: Product Profile - Sovaldi
Table 66: Efficacy of Sovaldi - SVR12, Key Phase III Trials
Table 67: Safety of Sovaldi - Most Common AEs
Table 68: Sovaldi SWOT Analysis, 2016
Table 69: Global Sales Forecast ($m) for Sovaldi, 2015-2025
Table 70: Daklinza - Key Clinical Trials Supporting Regulatory Approval
Table 71: Product Profile - Daklinza
Table 72: Efficacy of Daklinza - SVR12, Key Phase IIb and III Trials
Table 73: Safety of Daklinza - Most Common AEs
Table 74: Daklinza SWOT Analysis, 2016
Table 75: Global Sales Forecast ($m) for Daklinza, 2015-2025
Table 76: Olysio - Key Clinical Trials Supporting Regulatory Approval
Table 77: Product Profile - Olysio
Table 78: Efficacy of Olysio - SVR12, Key Phase III and Phase II Trials
Table 79: Safety of Olysio - Most Common AEs in Clinical Trials
Table 80: Olysio SWOT Analysis, 2016
Table 81: Global Sales Forecasts ($m) for Olysio, 2015-2025
Table 82: Product Profile - Pegasys
Table 83: Product Profile - PegIntron
Table 84: Efficacy of Pegasys with or without Ribavirin Compared with Interferon Alfa-2b
Table 85: Efficacy of PegIntron Compared With Interferon Alfa-2b
Table 86: Pegasys and PegIntron SWOT Analysis, 2016
Table 87: Global Sales Forecast ($m) for Pegasys, 2015-2025
Table 88: Global Sales Forecast ($m) for PegIntron, 2015-2025
Table 89: Ribavirin SWOT Analysis, 2016
Table 90: Global Sales Forecast ($m) for Copegus, 2015-2025
Table 91: Global Sales Forecast ($m) for Rebetol, 2015-2025
Table 92: Summary of Other Branded DAAs, 2016
Table 93: Unmet Needs and Opportunities in Chronic Hepatitis C
Table 94: Hepatitis C Virus Infection - Late-Stage Pipeline, 2016
Table 95: Key Clinical Trials of Gilead’s Sofosbuvir/Velpatasvir/Voxilaprevir Combination
Table 96: Product Profile - Sofosbuvir/Velpatasvir/Voxilaprevir
Table 97: Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Phase II Clinical Trials
Table 98: Sofosbuvir/Velpatasvir/Voxilaprevir SWOT Analysis, 2016
Table 99: Global Sales Forecast ($m) for Sofosbuvir/Velpatasvir/Voxilaprevir, 2015-2025
Table 100: Phase III Clinical Trials of AbbVie’s Glecaprevir/Pibrentasvir Combination
Table 101: Product Profile - Glecaprevir/Pibrentasvir
Table 102: Efficacy of Glecaprevir/Pibrentasvir in Phase II Trials
Table 103: Most Common AEs of Glecaprevir/Pibrentasvir in Phase II Trials
Table 104: Glecaprevir/Pibrentasvir SWOT Analysis, 2016
Table 105: Global Sales Forecast ($m) for Glecaprevir/Pibrentasvir, 2015-2025
Table 106: Phase III Clinical Trials of BMS’s Asunaprevir/Beclabuvir/Daclatasvir
Table 107: Product Profile - Asunaprevir/Beclabuvir/Daclatasvir
Table 108: Efficacy of Asunaprevir/Beclabuvir/Daclatasvir in Phase III Clinical Trials
Table 109: Efficacy of Asunaprevir/Beclabuvir/Daclatasvir in Japanese Patients
Table 110: Asunaprevir/Beclabuvir/Daclatasvir SWOT Analysis, 2016
Table 111: Global Sales Forecast ($m) for Asunaprevir/Beclabuvir/Daclatasvir, 2015-2025
Table 112: On-Going Phase II Clinical Trials of MK-3682A and MK-3682B
Table 113: Product Profile - MK-3682A and MK-3682B
Table 114: Efficacy of MK-3682A and MK-3682B in Phase II Trials
Table 115: MK-3682A and MK-3682B SWOT Analysis, 2016
Table 116: Global Sales Forecasts ($m) for MK-3682A and MK-3682B, 2015-2025
Table 117: Phase II Clinical Trials involving Achillion and Janssen’s Odalasvir
Table 118: Product Profile - AL-335/odalasvir/simeprevir
Table 119: AL-335/Odalasvir/Simeprevir SWOT Analysis, 2016
Table 120: Global Sales Forecast ($m) for AL-335/Odalasvir/Simeprevir, 2015-2025
Table 121: Other Products in Clinical Development for HCV Infection, 2016
Table 122: Clinical Development outside 9MM, 2016
Table 123: Key Companies in the HCV Marketplace in the 9MM, 2016
Table 124: Gilead’s HCV Portfolio Assessment, 2016
Table 125: AbbVie’s HCV Portfolio Assessment, 2016
Table 126: Merck’s HCV Portfolio Assessment, 2016
Table 127: Janssen’s HCV Portfolio Assessment, 2016
Table 128: BMS’ HCV Portfolio Assessment, 2016
Table 129: Roche’s HCV Portfolio Assessment, 2016
Table 130: Regulus’ HCV Portfolio Assessment, 2016
Table 131: Presidio’s HCV Portfolio Assessment, 2016
Table 132:Trek Therapeutics’ HCV Portfolio Assessment, 2016
Table 133: Global (9MM) Sales Forecast ($m) for Hepatitis C, 2015-2025
Table 134: 9MM Chronic Hepatitis C Market - Drivers and Barriers, 2015-2025
Table 135: US Sales Forecast ($m) for Hepatitis C, 2015-2025
Table 136: Key Events Impacting Sales for Chronic Hepatitis C in the US, 2015-2025
Table 137: Chronic Hepatitis C Market - Drivers and Barriers in the US, 2015-2025
Table 138: 5EU Sales Forecast ($m) for Hepatitis C, 2015-2025
Table 139: Key Events Impacting Sales for Chronic Hepatitis C in the 5EU, 2015-2025
Table 140: Chronic Hepatitis C Market - Drivers and Barriers in the 5EU, 2015-2025
Table 141: France Sales Forecast ($m) for Hepatitis C, 2015-2025
Table 142: Key Events Impacting Sales for Chronic Hepatitis C in France, 2015-2025
Table 143: Chronic Hepatitis C Market - Drivers and Barriers in France, 2015-2025
Table 144: Germany Sales Forecasts ($m) for Hepatitis C, 2015-2025
Table 145: Key Events Impacting Sales for Chronic Hepatitis C in Germany, 2015-2025
Table 146: Chronic Hepatitis C Market - Drivers and Barriers in Germany, 2015-2025
Table 147: Italy Sales Forecast ($m) for Hepatitis C, 2015-2025
Table 148: Key Events Impacting Sales for Chronic Hepatitis C in Italy, 2015-2025
Table 149: Chronic Hepatitis C Market - Drivers and Barriers in Italy, 2015-2025
Table 150: Spain Sales Forecast ($m) for Hepatitis C, 2015-2025
Table 151: Key Events Impacting Sales for Chronic Hepatitis C in Spain, 2015-2025
Table 152: Chronic Hepatitis C Market - Drivers and Barriers in Spain, 2015-2025
Table 153: UK Sales Forecasts ($m) for Hepatitis C, 2015-2025
Table 154: Key Events Impacting Sales for Chronic Hepatitis C in the UK, 2015-2025
Table 155: Chronic Hepatitis C Market - Drivers and Barriers in the UK, 2015-2025
Table 156: Japan Sales Forecast ($m) for Hepatitis C, 2015-2025
Table 157: Key Events Impacting Sales for Chronic Hepatitis C in Japan, 2015-2025
Table 158: Chronic Hepatitis C Market - Drivers and Barriers in Japan, 2015-2025
Table 159: Brazil Sales Forecast ($m) for Hepatitis C, 2015-2025
Table 160: Key Events Impacting Sales for Chronic Hepatitis C in Brazil, 2015-2025
Table 161: Chronic Hepatitis C Market - Drivers and Barriers in Brazil, 2015-2025
Table 162: China Sales Forecast ($m) for Hepatitis C, 2015-2025
Table 163: Key Events Impacting Sales for Chronic Hepatitis C in China, 2015-2025
Table 164: Chronic Hepatitis C Market - Drivers and Barriers in China, 2015-2025
Table 165 Key Historical and Projected Launch Dates for Chronic Hepatitis C
Table 166 Key Historical and Projected Patent Expiry Dates for Chronic Hepatitis C
Table 167: High Prescribers Surveyed
1.2 List of Figures
Figure 1: HCV Genome and Polyprotein Composition
Figure 2: HCV Lifecycle Overview
Figure 3: 9MM, Anti-HCV+ Total Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015-2025
Figure 4: 9MM, Anti-HCV+ Total Prevalent Cases, by Age, Both Sexes, N, 2015
Figure 5: 9MM, Anti-HCV+ Total Prevalent Cases, All Ages, by Sex, N, 2015
Figure 6: 9MM, Age-Standardized Anti-HCV+ Total Prevalence, All Ages, by Sex, %, 2015
Figure 7: 9MM, HIV and HBV Co-Infections Among Anti-HCV+ Total Prevalent Cases, All Ages, Both Sexes, N, 2015
Figure 8: 9MM, HCV RNA+ Total Prevalent Cases, All Ages, Both Sexes, N, Selected Years, 2015-2025
Figure 9: 9MM, HCV RNA+ Total Prevalent Cases, by Age, Both Sexes, N, 2015
Figure 10: 9MM, HCV RNA+ Total Prevalent Cases, by Sex, N, 2015
Figure 11: 9MM, Age-Standardized HCV RNA+ Total Prevalence, All Ages, by Sex, %, 2015
Figure 12: 9MM, Anti-HCV+ Diagnosed Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015-2025
Figure 13: 9MM, Age-Specific Anti-HCV+ Diagnosed Prevalent Cases, Both Sexes, N, 2015
Figure 14: 9MM, Anti-HCV+ Diagnosed Prevalent Cases, All Ages, by Sex, N, 2015
Figure 15: 9MM, Age-Standardized Anti-HCV+ Diagnosed Prevalence, All Ages, by Sex, %, 2015
Figure 16: 9MM, Anti-HCV+ Diagnosed Prevalent Cases by Liver Cirrhosis Status, All Ages, Both Sexes, N, 2015
Figure 17: 9MM, HCV RNA+ Diagnosed Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015-2025
Figure 18: 9MM, Age-Specific HCV RNA+ Diagnosed Prevalent Cases, Both Sexes, N, 2015
Figure 19: 9MM, HCV RNA+ Diagnosed Prevalent Cases, All Ages, by Sex, N, 2015
Figure 20: 9MM, Age-Standardized HCV RNA+ Diagnosed Prevalence, All Ages, by Sex, %, 2015
Figure 21: Hepatitis C - Clinical Trials by Status and Phase, 2016
Figure 22: HCV Infection Therapies - Phase II-III Pipeline, 2016
Figure 23: Competitive Assessment of Late-Stage Pipeline Agents for HCV Infection, 2015-2025
Figure 24: Clinical and Commercial Positioning of Sofosbuvir/Velpatasvir/Voxilaprevir
Figure 25: Clinical and Commercial Positioning of Glecaprevir/Pibrentasvir
Figure 26: Clinical and Commercial Positioning of Asunaprevir/Beclabuvir/Daclatasvir
Figure 27: Clinical and Commercial Positioning of MK-3682A and MK-3682B
Figure 28: Clinical and Commercial Positioning of Odalasvir-Based Regimens
Figure 29: Company Market Share in HCV, 2015 and 2025
Figure 30: Company Portfolio Gap Analysis in HCV, 2015-2025
Figure 31: Annual Global (9MM) Sales of DAAs, by Region, in 2015 and 2025
Figure 32: Annual Global (9MM) Sales of DAAs, by Brand, in 2015 and 2025
Figure 33: Annual Sales of DAAs in the US in 2015 and 2025
Figure 34: Annual Sales of DAAs in the 5EU in 2015 and 2025
Figure 35: Annual Sales of DAAs in France in 2015 and 2025
Figure 36: Annual Sales of DAAs in Germany in 2015 and 2025
Figure 37: Annual Sales of DAAs in Italy in 2015 and 2025
Figure 38: Annual Sales of DAAs in Spain in 2015 and 2025
Figure 39: Annual Sales of DAAs in the UK in 2015 and 2025
Figure 40: Annual Sales of DAAs in Japan in 2015 and 2025
Figure 41: Annual Sales of DAAs in Brazil in 2015 and 2025
Figure 42: Annual Sales of DAAs in China in 2025

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report